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Background: Transthyretin (TTR) gene mutations are the most common cause of hereditary amyloidosis. Valine replaced by isoleucine in 
position 122 (V122I) variant is common in the United States, present in up to 4% of the black population. V122I carriers are reported to be 
at high risk for development of cardiac amyloidosis and cardiomyopathy, particularly at older age. Despite a relatively high prevalence, the 
penetrance of V122I is not firmly established. In this study we sought to determine the prevalence of clinically apparent cardiac amyloidosis 
among carriers of the TTR V122I variant.
methods: BioVU, a Vanderbilt University resource linking DNA samples and pre-existing genetic data to de-identified electronic medical 
records was used to identify TTR V122I mutation carriers. Automated billing code queries (ICD-9 codes), problem list searches, and 
manual chart reviews were used to identify subjects with clinically diagnosed cardiac amyloidosis. Analysis was limited to black and white 
subjects. Statistical analysis was performed using Fisher’s exact test.
results: Amongst 28,429 subjects with available genotype data, 129 were V122I carriers. Carriers were 95% black, 61% female, median 
age of 42 years [IQR 16 to 64], age range 4 to 96 years. Non-carriers were 11% black, 53% female, median age of 62 years, [IQR 41 to 
77], age range 3 to 109 years. The carrier rate was 3.7% in blacks and 0.02% whites. Overall, the prevalence of clinically apparent cardiac 
amyloidosis was 0.8% in carriers and 0.04% in non-carriers (p=0.05). Above age 60 (N= 15,671, 7.8% black, 51% female, median age=75 
[IQR 67 to 75.3 years) the prevalence of cardiac amyloidosis was 2.6% in carriers and 0.06% in non-carriers (p=0.03).
conclusion:  Carriers of the TTR V122I variant are at a higher risk for development of cardiac amyloidosis, particularly at age>60 years. 
However, clinically apparent cardiac amyloidosis in this population was uncommon. Though limited by reliance on clinically acquired 
data and possible under-ascertainment, these results support that the penetrance of TTR V122I is age dependent and suggest it may be 
significantly lower than previously reported.
